Stock Events

Stock Events

Minerva Neurosciences 

$6.17
0
-$0.14-2.22% Tuesday 02:24

Statistics

Day High
6.17
Day Low
6.17
52W High
-
52W Low
-
Volume
8
Avg. Volume
-
Mkt Cap
43.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2025
Q4 2025
Next
-0.64
-0.47
-0.3
-0.13
Expected EPS
-0.1303
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
0Revenue
2.88MNet Income

Analyst Ratings

$7.00Average Price Target
The highest estimate is 7.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NERV.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Acadia Pharmaceuticals specializes in neurology, competing with Minerva in developing treatments for central nervous system disorders.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes works on central nervous system (CNS) diseases, including schizophrenia and depression, areas Minerva is also targeting.
BridgeBio Pharma
BBIO
Mkt Cap12.07B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs that could overlap with Minerva's focus on neurological conditions.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a major player in neurology, directly competing with Minerva in the broader market for neurological disease treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, with its broad focus on biopharmaceuticals, has ventures into neuroscience, making it a competitor in the neurology space.
Insmed
INSM
Mkt Cap40.44B
Insmed incorporates a wide range of therapeutic areas, including neurological diseases, indirectly competing with Minerva.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, which includes treatments for neurological disorders, competing with Minerva's focus.
Palatin Technologies
PTN
Mkt Cap2.45M
Palatin Technologies, though focused on different areas, has shown interest in expanding into central nervous system disorders, potentially competing with Minerva.

About

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
ISIN
US6033802058

Listings

F
DE
4MNA.F
XNAS
US
NERV
BOATS
BOATS
NERV.BOATS

0 Comments

Share your thoughts

FAQ

What is Minerva Neurosciences stock price today?▼
The current price of NERV.BOATS is $6.17 USD — it has decreased by -2.22% in the past 24 hours. Watch Minerva Neurosciences stock price performance more closely on the chart.
What is Minerva Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Minerva Neurosciences stocks are traded under the ticker NERV.BOATS.
What is Minerva Neurosciences market cap?▼
Today Minerva Neurosciences has the market capitalization of 43.15M
When is the next Minerva Neurosciences earnings date?▼
Minerva Neurosciences is going to release the next earnings report on May 06, 2026.
What were Minerva Neurosciences earnings last quarter?▼
NERV.BOATS earnings for the last quarter are -0.64 USD per share, whereas the estimation was -0.3 USD resulting in a -111.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Minerva Neurosciences revenue for the last year?▼
Minerva Neurosciences revenue for the last year amounts to 0 USD.
What is Minerva Neurosciences net income for the last year?▼
NERV.BOATS net income for the last year is 2.88M USD.
When did Minerva Neurosciences complete a stock split?▼
Minerva Neurosciences has not had any recent stock splits.